Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NDUFB4P4 is a human pseudogene, annotated as NADH:ubiquinone oxidoreductase subunit B4 pseudogene 4. Pseudogenes arise from gene duplication or retrotransposition events but typically do not encode functional proteins. Some pseudogenes are transcribed and can regulate protein-coding genes via noncoding RNA mechanisms (such as acting as microRNA decoys, antisense transcripts, or sources of small interfering RNAs). However, there is no evidence that NDUFB4P4 itself produces functional RNA or impacts cellular processes. Like many pseudogenes, it is retained in the genome without a clear protein-coding or therapeutic role. Key context: Pseudogenes in general may have subtle regulatory roles, but most do not encode functional gene products. NDUFB4 is a subunit of mitochondrial complex I, but NDUFB4P4 is a nonfunctional copy, not involved in respiratory chain activity or disease. No interaction with drugs, no biomarker status, and no therapeutic relevance are recorded for NDUFB4P4. In summary: NDUFB4P4 is a noncoding pseudogene, not a canonical therapeutic target, and should not be listed as a drug discovery or disease-related target.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADH:ubiquinone oxidoreductase subunit B4 pseudogene 4 (NDUFB4P4).